Parkinson disease

@article{Poewe2017ParkinsonD,
  title={Parkinson disease},
  author={W. Poewe and K. Seppi and C. Tanner and G. Halliday and P. Brundin and J. Volkmann and A. Schrag and A. Lang},
  journal={Nature Reviews Disease Primers},
  year={2017},
  volume={3}
}
  • W. Poewe, K. Seppi, +5 authors A. Lang
  • Published 2017
  • Medicine
  • Nature Reviews Disease Primers
  • Parkinson disease is the second-most common neurodegenerative disorder that affects 2–3% of the population ≥65 years of age. Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of α-synuclein are the neuropathological hallmarks of Parkinson disease. Multiple other cell types throughout the central and peripheral autonomic nervous system are also involved, probably from early disease onwards. Although clinical… CONTINUE READING
    48 Citations

    Paper Mentions

    OBSERVATIONAL CLINICAL TRIAL
    The purpose of this study is to evaluate how safinamide, rasagiline and other SoC drugs are associated with the quality of life of PD patients by means of the Parkinson's Disease… Expand
    ConditionsParkinson's Disease
    Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson's disease.
    • 19
    The genetics of Parkinson disease
    • 79
    Aging and Parkinson's Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis
    • 102
    • PDF
    Therapeutic approaches to target alpha-synuclein pathology
    • 99
    Quantitative susceptibility mapping differentiates between parkinsonian disorders.
    • 23
    Cicadidae Periostracum, the Cast-Off Skin of Cicada, Protects Dopaminergic Neurons in a Model of Parkinson's Disease
    • 3
    • PDF

    References

    SHOWING 1-10 OF 298 REFERENCES
    Parkinson's disease
    • 329
    Calcium and Parkinson's disease.
    • 86
    Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons
    • 449
    • PDF
    The Concept of Prodromal Parkinson’s Disease
    • 102
    • PDF
    Neuroinflammation in Parkinson's disease: a target for neuroprotection?
    • 1,298
    • PDF
    Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
    • 1,102
    Neuroimaging in Parkinson disease: from research setting to clinical practice
    • 133
    Are synucleinopathies prion-like disorders?
    • 207